GLP-1

MOST VIEWED

Illustration of an FDA warning featuring a weight-loss injection pen, a person measuring their waist, a warning sign, and a woman covering her eyes against a beige background.
Clinical Trials

FDA Puts All GLP-1 Drugs on NAION Watch

Regulators want a warning, neuro-ophthalmologists say don’t panic, and the mechanism is anyone’s guess.  The U.S. Food and Drug Administration (FDA) is requiring safety labeling changes for all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), giving the optic nerve a spot on the labels...
GLP-1 drugs in ophthalmology in a review study
Research & Evidence

GLP-1 Drugs and Ocular Disease: Between Neuroprotection and Risk

Weight-loss blockbuster or retinal wildcard? The ocular story behind GLP-1s is getting messier. GLP-1 therapies are showing up in ophthalmic practice whether clinicians are ready for them or not, and the evidence on their ocular effects is as mixed as the patients taking them. A recent Survey of Ophthalmology review synthesized findings from cardiovascular outcomes...
Untitled design 11
Retina

When the Pendulum Swings

Finding balance in the retinal effects of GLP-1 drugs Rapid metabolic change can tip the retina off balance before it finds its rhythm. In medicine, every breakthrough comes with a backswing. The harder we push the pendulum toward progress, the more forcefully it can swing back. Nowhere is that motion more literal than in the...

No entries were found for this taxonomy term.